Mati Therapeutics has designed and tested over 70 iterations of its L-shaped punctal plug drug delivery device (L-PPDS). The L-PPDS provides one-directional drug release into the tear film from a solid drug-eluting core wrapped in a non-permeable membrane. Testing shows retention rates of over 90% for the L-PPDS. Mati has formulated the L-PPDS to elute drugs for glaucoma, allergy, anti-inflammatory conditions, and dry eye over 2 weeks with a tunable initial burst. The company's intellectual property portfolio includes over 60 issued patents covering the device design and manufacturing through 2034.

1. M a t i T h e r a p e u t i c s I n c .
1
bbutchofsky@matitherapeutics.com cmuller@matitherapeutics.com

2.  Designed and tested over 70 different iterations including “arrow” and “L”
shapes among others
Barrel L Design Arrowhead L Design
Straight L Design
Arrow Design

3.  Retention rate of initial L-PPDS
 GLAU12 = 96%
 GLAU13 = 92%
 High Retention rate continues on repeat insertion of L-PPDS
 2nd cycle (8 weeks) = 97%

5.  Solid drug-eluting core placed into our silicon punctal plug
 Drug core wrapped in a non-permeable membrane and sealed with
medical adhesive
 Provides for one-directional drug release – directly into the tear film
X
X X

6. Glaucoma Allergy Anti-Inflammatory Dry Eye
Prostglandins Mast Cell Stabilizers Steroids Soft Steroids
Beta-Blockers Antihistamines NSAIDs NSAIDs
AlphaAgonists OTC Demulcents
NCEs (ROK?) NCEs

7. Glaucoma Allergy Anti-Inflammatory Dry Eye
Prostglandins
(Latanoprost,
Brimatoprost,
Travoprost)
Mast Cell Stabilizers Steroids Soft Steroids
Beta-Blockers Antihistamines NSAIDs
(Nepafenac,
Bromfenac)
NSAIDs
AlphaAgonists Olopatadine OTC Demulcents
NCEs (ROK?) NCEs
Mati now has 5 fully formulated ophthalmic agents including PGs, NSAIDs, and Mast
Cell Stabilizers/Antihistamines.

8. -6.09
-5.35 -5.44
-5.07
-5.56
-4.88
-5.3
-5.06
-7
-6
-5
-4
-3
-2
-1
0
WK 1 WK 2 WK 3 WK 4 WK 6 WK 8 WK 10 WK 12
95% CI*
Wk 4: (-6.11, -4.04), Wk 8: (-5.77, -3.99), Wk12:(-6.20, -3.93)
ChangeinIOP(mmHg)
*95% CI excludes 0, indicating a p-value of <.05All IOP included, regardless of plug loss/removal

9. Adverse Event Percentage
Lacrimation (tearing) 13.1%
Eye Pruritis (itching) 10.7%
Conjunctival Hyperemia (redness) 7.6%
Punctate Keratitis (form of cornea inflammation) 6.7%
Eyelid Erythema (redness) 1.7%
Photophobia (light sensitivity) 0.5%
All Studies at 95µg PlugConcentration or Less, N=421
Serious AEs
Serious Adverse Event Occurrence
Skin Erosion 1 patient
Systemic 2 patients

10. 0
2
4
6
8
10
12
14
0 5 10 15 20 25 30
DrugElutionRateug/day
Time (days)
L-PPDS
50% T-PPDS
30% T-PPDS

12. Beta-Blocker
Travoprost

13. 0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
0 5 10 15 20 25 30
Elutionrate(microg/day)
Time (Days)
• Target elution : 3 μg/day for two weeks
Target μg
For desired efficacy
Initial burst is tunable to extend
duration of action or power of
initial dose

14.  IP portfolio consists of 62 issued patents and approximately 106
pending applications, comprising 15 patent families:
▪ Drug Core Design and Formulation
▪ Lacrimal Implants
▪ Manufacturing
▪ Tools
▪ Method of Use
 Patent protection currently extends from approximately 2027-
2034

15. Formulation Preclinical Phase I Phase II Phase III
Evolute® Glaucoma
Latanoprost
Evolute® Glaucoma
Travoprost
Evolute® Allergy
(Olopatadine)
Evolute®
Anti-Inflammatory
(NSAID and/or steroid)
Multiple product opportunities for development from this platform
• Allergy, Inflammation (NSAIDs & Steroids), Glaucoma (PGs, BetaBlockers, CAIs, Alpha 2s), Dry Eye

16.  Wide Range of Compounds that can be Formulated
 Flexible Drug Delivery Profile
 Non-Invasive Approach
 Provides Relatively Steady Elution – Unlike Eye Drops
 Mati Plug is Comfortable and has Excellent Retention
 Preservative Free
 “Passive” System for Patients → Physician Controls Compliance
 Reimbursement Paradigm Shift for General Ophthalmologists, Glaucoma
Specialists, and Optometry
 Strong IP Protection
 Reasonable COGS Projections